Requirement of Apoptosis-Inducing Kinase 1 for the Induction of Bronchial Asthma following Stimulation with Ovalbumin

Eiko Takada a, Masae Furuhata a, Susumu Nakae c, Hidenori Ichijo d, Katsuko Sudo b, Junichiro Mizuguchi a

a Department of Immunology, and b Animal Research Center, Tokyo Medical University, and c Laboratory of Research Initiative, Institute of Medical Science, and d Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan

Abstract

Background: Bronchial asthma is a chronic inflammatory disease of the airway. Apoptosis signal-regulating kinase 1 (ASK1), a member of the mitogen-activated protein kinase kinase family, is activated by environmental stress and plays a crucial role in the induction of apoptosis and inflammation. To examine whether ASK1 is involved in the induction of bronchial asthma, we investigated the role of ASK1 using a genetic approach in the production of cytokines, as well as the development of airway hyperreactivity (AHR) and antibody responses using a murine airway inflammation model.

Methods: ASK1-deficient (ASK1−/−) and control wild-type (WT) mice were immunized with ovalbumin (OVA) without alum intraperitoneally, followed by intranasal administration of OVA. Airway infiltration of inflammatory cells, cytokine production, AHR and antibody production were assayed. The asthmatic phenotype was assessed following intranasal administration of IL-13 or TNF-α.

Results: ASK1−/− mice sensitized with OVA displayed an impaired inflammatory cell infiltration into airways and a decreased AHR relative to WT mice. Moreover, the production of OVA-specific IgE antibodies and proasthmatic cytokines (IL-5, IL-13 and TNF-α) was substantially reduced in OVA-stimulated ASK1−/− mice. Intranasal administration of IL-13 and OVA enhanced the accumulation of inflammatory cells in OVA-primed ASK1−/− mice. The OVA-induced AHR in response to methacholine was enhanced by IL-13 in WT mice but not ASK1−/− mice.

Conclusions: The ASK1 signaling pathway regulates the OVA-induced asthmatic phenotype, specifically AHR sensitivity and cytokine production. Therefore, the ASK1 signaling pathway is a promising target for therapeutic intervention in some asthmatic patients.

© 2013 S. Karger AG, Basel

Key Words
Asthma · Airway inflammatory disease · Apoptosis signal-regulating kinase 1 · Knock-out mice

Introduction

Bronchial asthma is a chronic inflammatory airway disease that is characterized by airway hyperreactivity (AHR), inflammatory cell infiltration and airway remodeling [1, 2]. This disease is initiated and aggravated by the infiltration of inflammatory cells such as T-helper 2 (Th2) cells, eosinophils, neutrophils and B cells [3]. Upon activation, Th2 cells produce IL-4, IL-5 and IL-13 [4]. IL-4 plays a crucial role in the differentiation and maintenance
of Th2 cells and stimulates B cells to produce IgE and IgG1 [5], while IL-13 is necessary for the effector phase of Th2 responses, including eosinophilia and hyperresponsiveness [6]. Th2 responses are regulated by a variety of factors, including transcription factors GATA3 and NF-κB, as well as mitogen-activated protein kinases (MAPKs) [7–9].

In mammalian cells, MAPKs are comprised of extracellular signal-regulated kinases, p38 MAPKs and c-Jun NH2-terminal kinases (JNKs) [8–11]. MAPKs are activated by a sequential phosphorylation from MAPK kinase kinases (MAP3Ks) to MAPK kinase (MAP2Ks) to MAPKs. Apoptosis signal-regulating kinase 1 (ASK1) is a member of the MAP3K protein family and plays a crucial role in the induction of apoptosis, cell proliferation and inflammation in some cell types [12]. We have recently demonstrated the role of ASK1 activation in the induction of apoptosis by engagement of membrane Ig on B cells [13]. Moreover, lipopolysaccharide binding to Toll-like receptor (TLR)4 activated the ASK1-p38 MAPK signaling pathway and resulted in inflammatory responses [14]. The pattern recognition receptors, TLRs and cytosolic nuclear binding/oligomerization domain leucine-rich repeat proteins are utilized by the innate immune systems to detect pathogen-associated molecular patterns, which are highly conserved modules produced by invading pathogens [15].

In the present study, we employed ASK1-deficient (ASK1−/−) mice to determine whether ASK1 activation is involved in the induction of bronchial asthma in response to ovalbumin (OVA) stimulation. ASK1 activation is necessary for the production of proinflammatory cytokines such as IL-5, IL-13 and TNF-α in BAL fluid. Signaling via ASK1 plays a crucial role in the induction of bronchial asthma, likely through cytokine production and AHR. Therefore, the ASK1 signaling pathway would be a suitable therapeutic target for the treatment of antigen-induced bronchial asthma.

Materials and Methods

Mice

ASK1−/− mice (C57BL/6 background) and control wild-type (WT) mice were bred and maintained at the animal facility of Tokyo Medical University. Experiments were approved by the Ethical Committee of Animal Experiments of Tokyo Medical University.

Histological Analysis of Lung Sections

Lungs were inflated with 4% (v/v) formalin/PBS solution (pH 7.0), embedded in paraffin, and sections were cut for standard HE and PAS staining.

Role of ASK1 in Bronchial Asthma

OVA-Induced Airway Inflammation

ASK1−/− and WT mice were sensitized with an intraperitoneal injection of 10 μg of OVA (grade V; Sigma-Aldrich, St. Louis, Mo., USA) suspended in PBS (0.2 ml) on days 0, 3, 5, 7, 9, 11 and 13. Control mice received the same volume of PBS. Mice were subjected to an intranasal challenge of 200 μg OVA or PBS on days 31, 34 and 37. At 24 h after the last serial OVA administration (day 38), histological sections, AHR, cytokine production, cell proliferation and Ab production were assayed.

Collection and Differentials of BAL Fluid-Derived Cells

The airways of the mice were lavaged three times with 1.0 ml of 2% fetal bovine serum in PBS via a tracheal cannula. BAL fluid was centrifuged and cells were resuspended in 0.5 ml of 2% fetal bovine serum in PBS. Differential cell counts were carried out using the Systex XT-2000iv automated cell counter (Systex Corporation, Kobe, Japan).

Measurement of AHR

Airway responsiveness was assessed using a slightly modified invasive approach using Buxco Research Systems (Wilmington, N.C., USA) as previously reported by Hamelmann et al. [16]. Briefly, in vivo lung resistance (R L) was measured in mice that were anesthetized with xylazine (10 mg/kg body weight)/ketamine (100 mg/kg body weight), tracheotomized and connected to a ventilator. Mice were ventilated with a tidal volume of 0.25 ml and 2 cm H2O positive end-expiratory pressure. Data before methacholine challenge were collected for 3 min to establish the baseline for each animal. Data regarding R L were collected for 3 min after aerosolized methacholine challenge (0, 3.125, 6.25, 12.5, 25 and 50 mg/ml). The mean response for each dose of methacholine was determined and R L was calculated by the percent change from baseline after PBS aerosol treatment.

Ab Quantification by Enzyme-Linked Immunosorbent Assay

Serum Ig levels were determined by enzyme-linked immunosorbent assay (ELISA) according to a modified procedure as previously described [17].

Measurement of Cytokine Levels

The levels of IFN-γ, TNF-α, IL-4, IL-5, IL-6, IL-10 and IL-12 in BAL fluid were determined using the Meso Scale Discovery Platform (Gaithersburg, Md., USA), according to the manufacturer’s recommendations. ELISA Ready Set (eBioscience, San Diego, Calif., USA) was used for measurement of IL-13, IL-17 and TNF-α. To measure the cytokine production by spleen cells, 4 × 10⁶/ml cells were plated in 24-well plates (1 ml/well) and cultured with or without 40 μg/ml of OVA for 72 h, and supernatants were assayed by ELISA for IL-13 and TNF-α production.

3H-Thymidine Incorporation in vitro

Single cell suspensions were prepared from the spleens of mice that were primed with or without OVA by teasing. Cells (4 × 10⁶/ ml) were cultured in 96-well plates with 40 μg/ml of OVA for 72 h and pulsed with 1 μCi (1 mCi = 37 MBq) 3H-thymidine/well for the final 8 h. The incorporated 3H-thymidine was counted in a liquid scintillation counter.
**Flow Cytometric Analysis of Cytokine Production**

Cells from BAL fluid were stained with APC-anti-CD11c and FITC-anti-Gr1, followed by fixation and permeabilization using Fixation and Permeabilization Solution (BD Bioscience, San Jose, Calif., USA). Then, cells were stained with PE-anti-TNF-α (Bio-Legend, San Diego, Calif., USA) or PE-anti-IL-13 (eBioscience), and subjected to flow cytometric analysis (FACSCalibur, Nippon Becton Dickinson Company Ltd., Tokyo, Japan).

**Intranasal Administration of IL-13 or TNF-α**

Mice primed with or without OVA were anesthetized with 2% isoflurane and then challenged with intranasal administration of TNF-α (50 ng/20 μl PBS with 0.1% BSA/mouse, once) or IL-13 (1 μg/20 μl PBS with 0.1% BSA/mouse, daily for 3 consecutive days). BAL and AHR were determined 24 h after the administration of TNF-α or IL-13.

**Statistical Analysis**

Data are expressed as means ± SD for each group. Statistical significance was determined by Student’s t test.

---

**Fig. 1.** The OVA-induced bronchial asthma phenotype is compromised in ASK1−/− mice. Mice were sensitized by an intraperitoneal injection of 10 μg of OVA in PBS 7 times, followed by intranasal administration of OVA or PBS. The day after the final OVA instillation, inflammatory cell infiltration in the airways was assessed. **a** Representative lung sections from ASK1−/− and control WT mice were stained with HE (×100 and ×200, as indicated). **b** Total cells in BAL fluid from ASK1−/− and control WT mice are shown. Data are representative of 3 independent experiments of 10 mice/group. Error bars represent the SD. *p < 0.05.

**Results**

*Attenuation of OVA-Induced Bronchial Pulmonary Pathologies and Decreased Inflammatory Cell Infiltration in ASK1−/− Mice*

ASK1−/− and WT mice were sensitized with OVA or left untreated and subsequently challenged with OVA aerosol or PBS alone. At 24 h after the final challenge, the mice were assayed for lung pathology and BAL cellularity. Control WT mice developed inflammatory lesions in the peribronchial and perivascular regions in response to OVA; however, the extent of the inflammatory lesion was reduced in ASK1−/− mice (fig. 1a). Goblet cell hyperplasia, as assessed by PAS staining, was also attenuated in OVA-stimulated ASK1−/− mice relative to the control [Takada et al., unpubl. observation]. OVA-induced bronchial asthma was accompanied by an accumulation of cells in the airway. The number of total cells and eosinophils accumulated in the airways of ASK1−/− mice was reduced rela-
Role of ASK1 in Bronchial Asthma

Int Arch Allergy Immunol 2013;162:104–114
DOI: 10.1159/000353240

107

tive to WT mice (fig. 1b). These results indicate that OVA-induced pulmonary inflammatory responses are attenuated in ASK1−/− mice.

**OVA-Induced Enhancement of AHR in Response to Methacholine Is Decreased in ASK1−/− Mice**

The dose-dependent change in RL following methacholine challenge was substantially higher in WT mice treated with OVA aerosol than mice treated with PBS alone (fig. 2). In contrast, the administration of OVA aerosol to ASK1−/− mice decreased the dose-dependent change in RL following methacholine challenge compared with controls. Therefore, in addition to the regulation of inflammatory cell infiltration, ASK1 also regulates the development of AHR.

**OVA-Induced IgE Production Is Attenuated in ASK1−/− Mice**

Since bronchial asthma is closely associated with IgE antibody production [4], Ab levels in sera from OVA-stimulated ASK1−/− and control WT mice were determined by ELISA. Anti-OVA-specific IgE Ab production in ASK1−/− mice was considerably reduced compared with control WT mice. This appeared to be specific to IgE since other isotypes of anti-OVA-specific Abs such as IgM, IgG1 and IgG2a [also IgG2b and IgG3; Takada et al., unpubl. observation] were not statistically different between ASK1−/− and WT mice (fig. 3). These results suggest that ASK1 regulates IgE Ab production in the mouse model of OVA-induced airway inflammatory disease.

**OVA-Induced Th2 Cytokine Production Is Attenuated in BAL Fluid from ASK1−/− Mice**

Since IgE Ab production is regulated by Th2 cytokines [5], we assayed cytokine levels in the BAL fluid from OVA-stimulated mice by ELISA. ASK1−/− mice produced diminished levels of IL-5 and IL-13 relative to WT mice, although comparable levels of IL-4 were produced (fig. 4a). TNF-α levels were also substantially reduced in ASK1−/− mice. Levels of other cytokines including IFN-γ, IL-6, IL-10, IL-12 and IL-17A were largely comparable between ASK1−/− and WT mice (fig. 4a) [unpubl. observation].

To assess the population of cytokine-producing cells in BAL fluids, IL-13- or TNF-α-producing cells were determined by flow cytometry (fig. 4b). Similar to previous reports by de Heer et al. [18], we detected several percentages of macrophages (Gr-1+, CD11c+) and lymphocytes (Gr-1−, CD11c−) producing TNF-α or IL-13, or both, in control mice. The frequency of these cells was substantially reduced in ASK1−/−, such that we detected percentage macrophages and percentage lymphocytes producing TNF-α or IL-13, or both. We confirmed these cells as macrophages and lymphocytes by Giemsa staining [Takada et al., unpubl. observation]. These findings suggest that ASK1 regulates the recruitment of cytokine-secreting cells into bronchial airways.

**IL-13 Production by OVA-Stimulated ASK1−/− Spleen Cells ex vivo Is Substantially Reduced**

To examine whether cytokine production in secondary lymphoid organs is also regulated by ASK1, spleen cells from the OVA-stimulated mice were cultured with or without OVA for 72 h in vitro, and then assayed for the production of IL-13 and TNF-α. Although OVA induced the production of IL-13 by ASK1−/− cells, the level was decreased relative to WT cells. The production of TNF-α by ASK1−/− cells and WT cells was similar (fig. 5a). OVA-induced proliferation of spleen cells was comparable between ASK1−/− and the control group (fig. 5b). Thus, ASK1 does not regulate the proliferation of splenocytes or the production of TNF-α in response to antigenic stimulation, but rather specifically regulates IL-13 production.

Fig. 2. OVA-induced enhancement of AHR in response to methacholine is compromised in ASK1−/− mice. Mice sensitized with OVA were assayed for AHR in response to various concentrations of methacholine. Data are representative of 3 independent experiments of 5–10 mice/group. Error bars represent the SD. *p < 0.05.
Intranasal Administration of IL-13 Restores Inflammatory Cell Accumulation in the Airways of OVA-Stimulated ASK1−/− Mice

To examine whether the diminished cytokine levels are responsible for the OVA-induced asthmatic phenotype in ASK1−/− mice, IL-13 was administered intranasally into the OVA-primed ASK1−/− and WT mice together, with or without stimulation with OVA, and BAL cells were enumerated. As shown in figure 6, the accumulation of inflammatory cells, including eosinophils, neutrophils, macrophages and lymphocytes, was diminished in ASK1−/− mice relative to WT mice. The intranasal coadministration of IL-13 and OVA to OVA-primed ASK1−/− mice restored inflammatory cell accumulation in ASK1−/− airways to levels comparable to that of WT mice. IL-13 alone had a minor effect on eosinophil accumulation in both ASK1−/− and WT mice (fig. 6). Likewise, the intranasal administration of TNF-α plus OVA into the OVA-primed ASK1−/− mice partially restored the accumulation of eosinophils, with limited impact on the accumulation of neutrophils and lymphocytes. Interestingly, TNF-α increased OVA-induced macrophage recruitment in control WT mice and ASK1−/− mice, suggesting that ASK1 regulates recruitment of macrophages into the airways via the production of TNF-α. These results suggest that ASK1 regulates cytokine production and the recruitment of inflammatory cells into the airways, which contribute to the asthmatic phenotype.

Intranasal Administration of IL-13 Induces AHR in WT, but Not ASK1−/− Mice

Intranasal administration of IL-13 has previously been shown to increase AHR [19]. We sought to determine whether intranasal administration of IL-13 to ASK1−/− mice could induce AHR in response to methacholine. As expected, the administration of IL-13 to unprimed WT mice resulted in a significant increase in AHR, which was not observed in ASK1−/− mice (fig. 7). Administration of TNF-α alone showed a similar tendency to cause an increase in AHR, although this was not statistically significant [unpubl. observation]. These results suggest that ASK1−/− mice are largely resistant to cytokine-induced increases in AHR. Together, ASK1 regulates airway hypersensitivity in response to cytokines as well as antigenic stimulation (OVA).

Discussion

Recent studies demonstrate the efficacy of p38MAPKs (SB239063) and JNK (SP600125) inhibitors using the animal models of bronchial asthma [20, 21]. Moreover, JunB has been reported to participate in the development of Th2 immune responses [22]. However, interpretation of these data needs careful consideration because of possible nonspecific effects of inhibitors used. Thus, we took...
a genetic approach in vivo to investigate the role of MAPKs cascade using mice deficient in ASK1, an upstream component of JNKs and p38MAPKS, on an antigen-induced asthma. The OVA-induced accumulation of inflammatory cells into the airways, including eosinophils, lymphocytes, macrophages and neutrophils, was attenuated in ASK1−/− mice relative to WT mice. In addition, OVA-induced increase of AHR in response to methacholine was also reduced in ASK1−/− mice, suggesting that antigen-induced airway inflammation is accompanied by an increase in AHR to methacholine, as previously proposed [23]. Thus, ASK1 appears to regulate the bronchial asthmatic phenotype in C57BL/6 mice in response to OVA without alum via modulation of downstream signaling pathways. Bronchial asthmatic phenotypes including antigen-induced increase in Th2 cytokine production in response to an environmental antigen are regulated by several transcription factors, such as GATA3, Stats, NF-κB and AP-1 [7, 24, 25]. AP-1, consisting of c-Jun and Fos, is activated by p38 MAPK and the JNK sig-

**Fig. 4.** Cytokine profile of the BAL fluid and cells from ASK1−/− and control WT mice sensitized with OVA. BAL fluids from OVA-sensitized ASK1−/− and control WT mice were assayed for cytokines by ELISA. Data are representative of 3 independent experiments of 5 mice/group. Error bars represent the SD. * p < 0.05.
**Fig. 4.** Cytokine profile of the BAL fluid and cells from ASK1<sup>−/−</sup> and control WT mice sensitized with OVA. 

b The proportion of IL-13-producing lymphocytes and TNF-α-producing macrophages or lymphocytes in BAL fluids from the OVA-sensitized ASK1<sup>−/−</sup> and control WT mice. Data are representative of 3 independent experiments of 5 mice/group. Error bars represent the SD. * p < 0.05.

**Fig. 5.** IL-13 production by ASK1<sup>−/−</sup> spleen cells is diminished relative to controls. Spleen cells from OVA-sensitized ASK1<sup>−/−</sup> mice and control WT mice were cultured with 40 μg/ml of OVA or medium alone. IL-13 and TNF-α (a) and <sup>3</sup>H-thymidine incorporation (b) were assayed after 72 h. Data are representative of 3 independent experiments of 3 mice/group. Error bars represent the SD. * p < 0.05.
**Fig. 6.** Intranasal administration of IL-13 or TNF-α restores OVA-induced inflammatory cell infiltration into the airways. The mice primed with OVA received intranasal administration of OVA or PBS in the presence or absence of IL-13 (1 μg/mouse) or TNF-α (50 ng/mouse). One day after the final challenge, the accumulation of cells in the BAL fluid was assayed. Data are representative of 3 independent experiments of 5–7 mice/group. Error bars represent the SD. * p < 0.05.
naling pathway, which in turn are regulated by upstream kinases, including the MAP2Ks and MAP3Ks, such as ASK1 [8, 11, 12]. In BAL fluid from ASK1−/− mice the levels of IL-5 and IL-13, but not IL-4, were moderately decreased compared with control WT mice. The reduced production of IL-5 in ASK1−/− mice likely contributed to the impaired accumulation of eosinophils in their BAL fluid because IL-5 and eotaxin regulate the recruitment of eosinophils into airways [26, 27]. Divergent production of IL-4 and IL-13 was found among innate immune cells: innate Th2 cells produce IL-13 and basophils produce IL-4 [28], although the production of IL-4, IL-5 and IL-13 by Th2 cells is regulated by GATA3 and Stat6 together with IL-2-mediated Stat5. Indeed, OVA-induced IL-13 production by spleen cells and the frequency of IL-13-producing cells in the airways were also decreased in ASK1−/− mice. Which types of cells produce IL-4 remains unclear in the present study.

IL-13 is a critical mediator of asthma pathology, including accumulation of inflammatory cells into the airway and IgE antibody responses [4, 6, 7]. Intranasal administration of IL-13 into OVA-stimulated ASK1−/− mice enhanced the accumulation of inflammatory cells (including eosinophils) in BAL fluid to levels similar to WT mice. Eosinophils reportedly play a crucial role in Th2 immune responses [29] through the recruitment of Th2 cells, which creates a positive feedback loop. Thus, ASK1 regulates the production of Th2 cytokines (IL-13 and IL-5) in response to OVA, and the accumulation of inflammatory cells in the airway and IgE antibody production.

In addition to typical Th2 cytokines IL-4, IL-5 and IL-13, TNF-α is reported to play a crucial role in the induction of bronchial asthma in some contexts [1, 25, 30]. The levels of the proinflammatory cytokine TNF-α were substantially suppressed in ASK1−/− BAL fluid, but not in sera [unpubl. observation]. Moreover, the proportion of TNF-α-producing cells in ASK1−/− BAL fluid was decreased, although OVA-sensitized ASK1−/− spleen cells have the capacity to produce TNF-α to levels equal to WT mice in response to OVA stimulation in vitro, suggesting that ASK1 regulates the recruitment of TNF-α-producing cells into the airway lesion. However, TNF-α production by ASK1−/− spleen cells in response to lipopolysaccharide stimulation was reportedly considerably decreased [14]. These data suggest that the requirement for ASK1 differs based on the stimulant, for example a TLR ligand versus an allergen.

TNF-α treatment of OVA-primed ASK1−/− mice partially restored the accumulation of eosinophils. This is in line with previous studies that reported a role for TNF-α in the development of the asthmatic phenotype in response to some antigens without alum [25, 31, 32]. However, it is important to note that different results have been reported in other experimental settings, suggesting that the role of TNF-α for the induction of the asthmatic phenotype was dependent on the genetic background of the mouse model and adjuvant used for immunization [30, 33].

Cytokine-mediated inflammatory reaction as well as structural changes in the airways regulates development of AHR [34, 35]. For example, IL-13 has been reported to increase in AHR to methacholine [19]. However, naïve ASK1−/− mice did not respond to IL-13 to display an increase in AHR, although such an increase in AHR was found in control WT mice, suggesting that ASK1 regulates AHR sensitivity to methacholine in a murine OVA-induced asthma model. Indeed, IL-13 directly activated bronchial smooth muscle cells [19, 36], leading to an increase in AHR. It is possible that IL-13-mediated activation of smooth muscle cells involves the ASK1 activation pathway. Together, ASK1 appears to regulate the asthmatic phenotype, probably through multiple events including cytokine production in peripheral lymphoid organs, recruitment of cytokine-producing cells in the airway, and sensitivity to cytokine to undergo an increase in AHR.
Our present results clearly demonstrate that ASK1 is involved in the induction of OVA-induced bronchial asthma in vivo. Although most asthmatic patients respond well to the current treatment of inhaled corticosteroid and β-adrenergic agents, some patients with severe disease are refractory to such treatments [37]. Thus, new treatment modalities are required for the refractory asthma phenotypes. Steroid-resistant asthmatics demonstrated elevated levels of JNK and AP1 [38, 39], which is proposed to neutralize activated glucocorticoid receptor, resulting in refractoriness to glucocorticoid-induced suppressive effects, suggesting that therapeutic targeting of the JNK-AP1 pathway [40] is an effective treatment modality for corticosteroid-resistant asthma. Indeed, both JNK1/− and JNK2/− mice showed a diminished bronchial asthmatic phenotype in response to OVA [Takada et al., unpubl. observation]. Together, our present studies demonstrated that ASK1-mediated signaling pathway(s) are a novel target for therapeutic intervention in some asthmatic patients.

**Acknowledgements**

This work was supported by a grant from the Intractable Immune System Disease Center of Tokyo Medical University, which is supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan.

**References**


Role of ASK1 in Bronchial Asthma


